Please try another search
Thinly traded Cidara Therapeutics (CDTX -19.6%) is down on over a 6x surge in volume following its release of Phase 2 data on lead antifungal candidate rezafungin acetate in patients with systemic...
Thinly traded micro cap Cidara Therapeutics (NASDAQ:CDTX) is unchanged premarket (was up over 20% earlier) on light volume on the heels of its announcement of positive results from a Phase 2 clinical...
Cidara Therapeutics (CDTX +2.4%) prices its direct sale of 3.36M shares of common stock to institutional investors at $6 per share yielding gross proceeds of ~$20M. Closing date is October...
Gainers: CLSN +44%. SRNE +17%. RWLK +12%. APRI +11%. TXMD +6%.Losers: XBIT -8%. EPZM -8%. AKER -8%. CDTX -8%. AHPI -7%.Now read: Why This Valeant Bull Doesn't Like The INova DealOriginal article
Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Utilities, Consumer Goods and Oil & Gas sectors led shares higher. At the close in NYSE, the Dow Jones Industrial...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review